The coronavirus (CoV) that causes severe acute respiratory syndrome, or SARS, is called SARS-CoV. CoVs, which are enveloped viruses with positive-sense, single-stranded RNA and can target the human respiratory system to spread disease, include not only the SARS virus but also MERS and SARS-CoV-2, which is the source of COVID-19.
The spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins are the four main structural proteins of CoVs. By binding to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), an S protein mediates the CoV entry into host cells, which is followed by the fusion of the virus and host cell membranes. Following entry, a large number of nonstructural proteins, including Mpro (main protease or 3CLpro), PLpro (papain-like protease), and RdRp (RNA-dependent RNA polymerase), participate in genome replication and subgenomic RNA transcription.The structural proteins are then translated, put together into mature virions, and exocytosed to release them via vesicles. It is noteworthy that a protease known as TMPRSS2 (transmembrane protease, serine 2), which cleaves S protein, plays crucial roles throughout the entire life of CoVs (such as attachment, assembling, and release). For the treatment of diseases brought on by CoVs, all the proteins and subcellular structures involved in the life cycle of CoVs are promising targets.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V76091 | SP inhibitor 1 | 2766185-81-1 | SP inhibitor 1 (compound 34) is a selective SARS-CoV-2 spike protein (SP) inhibitor (antagonist) with IC50s of 3.26 μM, >25 μM, and >25 μM for SP, Mpro, and PLpro proteins respectively. |
|
V79058 | SPR38 | SPR38 is a potent inhibitor of SARS-CoV-2 main protease with Ki of 0.260 μM. | |
|
V79074 | SPR39 | SPR39 is a potent SARS-CoV-2 main protease inhibitor, with Kis of 0.252, 3.38, and 7.88 µM for SARS-CoV-2 Mpro, hCatL, and hCatB respectively. | |
|
V78587 | SPR41 | SPR41 is a potent SARS-CoV-2 major protease inhibitor (antagonist) with Kis of 0.184, 0.252, and 14.4 µM for SARS-CoV-2 Mpro, hCatL, and hCatB respectively. | |
|
V54430 | SSAA09E1 | 433212-75-0 | SSAA09E1 is a cathepsin L (cathepsin L) blocker (IC50= 5.33 μM). |
|
V52986 | SSAA09E2 | 883944-52-3 | SSAA09E2 is a novel SARS-CoV replication inhibitor that works by blocking the early interaction of SARS-S with the SARS-CoV receptor angiotensin-converting enzyme-2 (ACE2). |
|
V35257 | SSAA09E3 | 52869-18-8 | SSAA09E3 is a SARS-CoV entry inhibitor that can suppress the entry of SARS/HIV pseudotyped viruses into 293T cells with EC50 of 9.7 μM. |
|
V35251 | STING agonist-30 | 2951078-67-2 | STING agonist-30 is a potent STING agonist. |
|
V54395 | Tanshinlactone | 105351-70-0 | Tanshinlactone is a secondary rosin compound that can be extracted from Salvia miltiorrhiza. |
|
V34737 | Teicoplanin sodium (Antibiotic MDL-507 sodium; MDL-507 sodium) | 184539-13-7 | Teicoplanin sodium (Antibiotic MDL-507 sodium) is an effective lipoglycopeptide antibiotic. |
|
V81552 | Telaprevir-d4 (VX-950-d4) | Telaprevir-d4 is the deuterium labelled form of Telaprevir. | |
|
V52568 | Tipranavir-d4 (tipranavir d4) | 1217819-15-2 | Tipranavir-d4 is the deuterium labelled form of Tipranavir. |
|
V54340 | tirfipiravir | 2759996-93-3 | Tirfipiravir is a nucleoside compound and antiviral compound that works against the novel coronavirus or influenza virus. |
|
V54377 | Tixagevimab (AZD8895) | 2420564-02-7 | Tixagevimab (AZD8895) is a human monoclonal antibody (mAb) that targets the SARS-CoV-2 receptor-binding domain (RBD). |
|
V54422 | TKB245 | 2892688-16-1 | TKB245 is a potent SARS-CoV-2 Mpro inhibitor that effectively blocks SARS-CoV-2 replication in VeroE6 cells. |
|
V81669 | Umifenovir-d6 hydrochloride (Arbidol d6 hydrochloride (hydrochloride)) | Umifenovir-d6 ( HCl) is the deuterium labelled form of Umifenovir HCl. | |
|
V35138 | Vilobelimab (CaCP-29, IFX-1) | 2250440-41-4 | Vilobelimab (CaCP-29, IFX-1) is a monoclonal antibody (mAb) against C5a, a proinflammatory complement cleavage product that plays a central role in mediating organ dysfunction. |
|
V35076 | Viral polymerase-IN-1 hydrochloride | 2367587-02-6 | Viral polymerase-IN-1 HCl is a Gemcitabine analogue that effectively inhibits influenza A and B virus (influenza) infection with an IC90 value of 11.4-15.9 μM. |
|
V4354 | VV116 | 2647442-33-7 | VV-116 (also known as VV116, JT-001) is a novel, potent and orally administered anti-SARS-CoV-2 nucleoside drug candidate (IC50 = 0.67±0.24 μM) acting asa viral RNA-dependent RNA polymerase (RdRp) inhibitor and isunder investigation for COVID-19 treatment in China. |
|
V54415 | WU-04 | 2921711-74-0 | WU-04 is a non-covalent inhibitor of SARS-CoV-2, targeting the 3CLpro protein. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
